If 68Ga-PSMA-11-PET/CT was indicated solely for metastatic prostate cancer or suspected metastases, the high rate of “no therapy” prior to these diagnostics could reflect an active-surveillance or wait-and-see approach following past treatments. This evidence concerns the gene FOLH1 and prostate cancer.